SEARCH

SEARCH BY CITATION

References

  • 1
    Zenner HP, Baumgarten C, Rasp G, et al. Short-term immunotherapy: a prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-indueed allergic rhinitis. J Allergy Clin Immunol 1997;100:239.
  • 2
    Brunet C, Bedard PM, Lavoie A, et al. Allergic rhinitis to ragweed pollen. I. Reassessment of the effects of immunotherapy on cellular and humoral responses. J Allergy Clin Immunol 1992; 89: 8794.
  • 3
    Turkeltaub PC, Campbell G, Mosimann JE. Comparative safety and efficacy of short ragweed extracts differing in potency and composition in the treatment of fall hay fever. Use of allergenically bioequivalent doses by parallel line bioassay to evaluate comparative safety and efficacy Allergy 1990;45:52846.
  • 4
    Wahn U, Schweter C, Lind P, Løwenstein H. Prospective study on immunologic changes induced by two different Dermalophagoides pteronyssinus extracts prepared from whole mite culture and mite bodies. J Allergy Clin Immunol 1988;82:36070.
  • 5
    Østerballe O. Immunotherapy with grass pollen major allergens. Allergy 1982;37:37988.
  • 6
    Haugaard L, Dahl R, Jacobsen L. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol 1993;91:70922.
  • 7
    Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991;302:2659.
  • 8
    MailingH-J, WeekeB, editors Immunotherapy. Position paper. EAACI Immunotherapy Subcommittee. Allergy 1993; 48 Suppl 14: 930.
  • 9
    European Economic Community (EEC). Note for guidance, good clinical practice for trials on medicinal products in the European Community. CPMP Working Party on Efficacy of Medicinal Products. Final approval 11.7.1990, date for coming into operation 1.7.1991. Pharmacol Toxicol 1990; 67: 36172.
  • 10
    World Medical Association. Declaration of Helsinki, Hongkong , 1989.
  • 11
    Gjesing B, Jäger L, Marsh DG, Løwenstein H. The international collaborative study establishing the first international standard for timothy (Phleum pratense)grass pollen allergenic extract. J Allergy Clin Immunol 1985;75:25867.
  • 12
    Sundin B, Lilja G, Graff-Lonnevig V, et al. Immunotherapy with partially purified and standardized animal dander extracts. I. Clinical results from a double-blind study on patients with animal dander asthma, J Allergy Clin Immunol 1986; 77: 47887.
  • 13
    Aas K, Backmann A, Belin L, Weeke B. Standardization of allergen extracts with appropriate methods. The combined use of skin prick testing and radio-allergosorbenttests. Allergy 1978; 33: 1307.
  • 14
    O'Brien PC. Procedures for comparing samples with multiple end points. Biometrics 1984;40:107987.
  • 15
    Lehmacher W, Wassmer G, Reitmeir P. Procedures for two-sample comparisons with multiple end points controlling the experimentwise error rate. Biometrics 1991;47:51121.
  • 16
    Nüchel-Petersen B, Janniche H, Munch EP et al. Immunotherapy with partially purified and standardized tree pollen extracts. Allergy 1988;43:35362.
  • 17
    Wihl JÅ, Ipsen H, Nüchel-Petersen B, Munch EP, Janniche H, Løwenstein H. Immunotherapy with partially purified and standardized tree pollen extracts. Allergy 1988;43:3639.
  • 18
    Fling JA, Ruff ME, Parker WA, et al. Suppression of the late cutaneous response by immunotherapy. J Allergy Clin Immunol 1989;83:1019.
  • 19
    Birkner T, Rumpold H, Jarolim E, et al. Evaluation of immunotherapy-induced changes in specific IgE, IgG and IgG subclasses in birch pollen allergic patients by means of immimoblotting. Correlation with clinical response. Allergy 1990; 45: 41826.
  • 20
    Parker WA, Wishman BA, Apaliski SJ, Reid MJ. The relationships between late cutaneous responses and specific antibody responses with outcome of immunotherapy for seasonal allergic rhinitis. J Allergy Clin Immunol 1989;84:66777.
  • 21
    Till S. Immunotherapy: readdressing the balance between TH2 and TH1 cells. Clin Exp Allergy 1997;27:9815.
  • 22
    Rak S, BjöJrnson A, Håkanson L, Sörenson S, Venge P. The effect of immunotherapy on eosinophil accumulation and production of eosinophil chemotactic activity in the lung of subjects with asthma during natural pollen exposure. J Allergy Clin Immunol 1991;88:87888.
  • 23
    Rak S, Löwhagen O, Venge P. The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients, J Allergy Clin Immunol 1988; 82: 47080.
  • 24
    Rasp G, Thomas A, Bujia J. Eosinophil inflammation of the nasal mucosa in allergic and non-allergic rhinitis measured by eosinophil cationic protein levels in native nasal fluid and serum. Clin Exp Allergy 1994;24:11516.